Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Biologics License Application (BLA) for its
investigational ragweed pollen (Ambrosia artemisiifolia)
sublingual allergy immunotherapy tablet has been accepted for review by
the U.S. Food and Drug Administration (FDA). On March 27, Merck
announced that the FDA had also accepted the BLA for its investigational Timothy
grass pollen (Phleum pratense) sublingual allergy immunotherapy
tablet.
Language:
English
Contact HTML:
MerckMedia:Pam Eisele, 908-423-5042Robert Consalvo, 908-423-6595orInvestor:Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Allergy | Allergy & Immunology | Food and Drug Administration (FDA) | Immunotherapy | Merck | Pharmaceuticals